Role of adenosine antagonism in the cardio-renal syndrome: Pathophysiology and therapeutic potential

Current Heart Failure Reports

Volumn 4, Issue 3, 2007, Pages 153-157

  Rajaram, Venkataraman ^b   Joseph, Jacob ^a  

^a VA BOSTON HEALTHCARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

6 OXO 3 (2 PHENYLPYRAZOLO[1,5 A]PYRIDIN 3 YL) 1(6H) PYRIDAZINEBUTYRIC ACID; 8 (2 NOR 1 ADAMANTYL) 1,3 DIPROPYLXANTHINE; ADENOSINE A1 RECEPTOR; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; CONTRAST MEDIUM; DIPYRIDAMOLE; FUROSEMIDE; NAXIFYLLINE; PLACEBO; THEOPHYLLINE;

CARDIO RENAL SYNDROME; CLINICAL TRIAL; DRUG EFFECT; DRUG INHIBITION; GLOMERULUS FILTRATION RATE; HEART DISEASE; HEART FAILURE; HUMAN; HYDRATION; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY FUNCTION; MONOTHERAPY; NONHUMAN; REVIEW; SEIZURE; UNSPECIFIED SIDE EFFECT;

ADENOSINE; ANIMALS; DIURESIS; HEART FAILURE; HUMANS; KIDNEY FAILURE; PROGNOSIS; RECEPTOR, ADENOSINE A1; RENAL CIRCULATION; VASODILATOR AGENTS;

EID: 34848895120     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-007-0034-1     Document Type: Review

References (42)

1. Acute Decompensated Heart Failure National Registry (ADHERE) Q1 2006 Final Cumulative National Benchmark Report. http://www.adhereregistry.com/ ADHEREQ102BMR_FINAL.pdf. Accessed June 20, 2007. This is a large, multicenter registry which details the epidemiology of acute HF and the prevalence of cardio-renal syndrome.
2. Cleland JG, Swedberg K, Follath F, et al.: The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003, 24:442-463.
3. Forman DE, Butler J, Wang Y, et al.: Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004, 43:61-67.
4. Weinfeld MS, Chertow GM, Stevenson LW: Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am Heart J 1999, 138:285-290.
5. Smith GL, Lichtman JH, Bracken MB, et al.: Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 2006, 47:1987-1996.
6. Leithe ME, Margorien RD, Hermiller JB, et al.: Relationship between central hemodynamics and regional blood flow in normal subjects and in patients with congestive heart failure. Circulation 1984, 69:57-64.
7. Francis GS, Benedict C, Johnstone DE, et al.: Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990, 82:1724-1729.
8. Francis GS, Siegel RM, Goldsmith SR, et al.: Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med 1985, 103:1-6.
9. Beutler JJ, Boer WH, Koomans HA, Dorhout Mees EJ: Renal hemodynamic and tubular response to furosemide in man during normal and restricted sodium intake. Nephron 1990, 54:208-213.
10. Gottlieb SS, Brater DC, Thomas I, et al.: BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 2002, 105:1348-1353.
11. Vallon V, Muhlbauer B, Osswald H. Adenosine and kidney function. Physiol Rev 2006, 86:901-940. This is an excellent overview of the physiologic role of adenosine and helps to understand the potential role of adenosine as a therapeutic target.
12. Kloor D, Kurz J, Fuchs S, et al.: S-adenosylhomocysteine-hydrolase from bovine kidney: enzymatic and binding properties. Kidney Blood Press Res 1996, 19:100-108.
13. Hansen PB, Schnermann J. Vasoconstrictor and vasodilator effects of adenosine in the kidney. Am J Physiol Renal Physiol 2003, 285:F590-599.
14. Fredholm BB, Ijzerman AP, Jacobson KA, et al.: International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001, 53:527-552.
15. Yamaguchi S, Umemura S, Tamura K, et al.: Adenosine A1 receptor mRNA in microdissected rat nephron segments. Hypertension 1995, 26:1181-1185.
16. Jackson EK, Zhu C, Tofovic SP. Expression of adenosine receptors in the preglomerular microcirculation. Am J Physiol Renal Physiol 2002; 283:F41-51.
17. Smith JA, Sivaprasadarao A, Munsey TS, et al.: Immunolocalisation of adenosine A(1) receptors in the rat kidney. Biochem Pharmacol 2001, 61:237-244.
18. Sun D, Samuelson LC, Yang T, et al.: Mediation of tubuloglomerular feedback by adenosine: evidence from mice lacking adenosine 1 receptors. Proc Natl Acad Sci U S A 2001, 98:9983-9988.
19. Brown R, Ollerstam A, Johansson B, et al.: Abolished tubuloglomerular feedback and increased plasma renin in adenosine A1 receptor-deficient mice. Am J Physiol Regul Integr Comp Physiol 2001, 281:R1362-367.
20. Kreisberg MS, Silldorff EP, Pallone TL: Localization of adenosine-receptor subtype mRNA in rat outer medullary descending vasa recta by RT-PCR. Am J Physiol 1997, 272:H1231-1238.
21. Vitzthum H, Weiss B, Bachleitner W, et al.: Gene expression of adenosine receptors along the nephron. Kidney Int 2004, 65:1180-1190.
22. Weaver DR, Reppert SM: Adenosine receptor gene expression in rat kidney. Am J Physiol 1992, 263:F991-995.
23. Zhou QY, Li C, Olah ME, et al.: Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor. Proc Natl Acad Sci U S A 1992, 89:7432-7436.
24. Linden J: Cloned adenosine A3 receptors: pharmacological properties, species differences and receptor functions. Trends Pharmacol Sci 1994, 15:298-306.
25. Dzau VJ: Renal and circulatory mechanisms in congestive heart failure. Kidney Int 1987, 31:1402-1415.
26. Elkayam U, Mehra A, Cohen G, et al.: Renal circulatory effects of adenosine in patients with chronic heart failure. J Am Coll Cardiol 1998, 32:211-215.
27. Wilcox CS, Welch WJ, Schreiner GF, Belardinelli L: Natriuretic and diuretic actions of a highly selective adenosine A1 receptor antagonist. J Am Soc Nephrol 1999, 10:714-720.
28. Schnackenberg CG, Merz E, Brooks DP: An orally active adenosine A1 receptor antagonist, FK838, increases renal excretion and maintains glomerular filtration rate in furosemide-resistant rats. Br J Pharmacol 2003, 139:1383-1388.
29. Gottlieb SS, Skettino SL, Wolff A, et al.: Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure. J Am Coll Cardiol 2000, 35:56-59.
30. Givertz MM, Massie BM, Fields TK, et al.: The effects of KW-3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with aculte decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol 2007, In press.
31. Weisbord SD, Chen H, Stone RA, et al.: Associations of increases in serum creatinine with mortality and length of hospital stay after coronary angiography. J Am Soc Nephrol 2006, 17:2871-2877.
32. Arend LJ, Bakris GL, Burnett JC Jr, et al.: Role for intrarenal adenosine in the renal hemodynamic response to contrast media. J Lab Clin Med 1987, 110:406-411.
33. Arakawa K, Suzuki H, Naitoh M, et al.: Role of adenosine in the renal responses to contrast medium. Kidney Int 1996, 49:1199-1206.
34. Erley CM, Duda SH, Rehfuss D, et al.: Prevention of radiocontrast-media-induced nephropathy in patients with pre-existing renal insufficiency by hydration in combination with the adenosine antagonist theophylline. Nephrol Dial Transplant 1999, 14:1146-1149.
35. Lee HT, Jan M, Bae SC, et al.: A1 adenosine receptor knockout mice are protected against acute radiocontrast nephropathy in vivo. Am J Physiol Renal Physiol 2006, 290:F1367-1375.
36. Kochanek PM, Vagni VA, Janesko KL, et al.: Adenosine A1 receptor knockout mice develop lethal status epilepticus after experimental traumatic brain injury. J Cereb Blood Flow Metab 2006, 26:565-575.
37. Lang UE, Lang F, Richter K, et al.: Emotional instability but intact spatial cognition in adenosine receptor 1 knock out mice. Behav Brain Res 2003, 145:179-188.
38. Morrison RR, Teng B, Oldenburg PJ, et al.: Effects of targeted deletion of A1 adenosine receptors on post-ishemic cardiac function and expression of adenosine receptor subtypes. Am J Physiol Heart Circ Physiol 2006, 291:H1875-1882.
39. Willems L, Reichelt ME, Molina JG, et al.: Effects of adenosine deaminase and A1 receptor deficiency in normoxic and ischaemic mouse hearts. Cardiovasc Res 2006, 71:79-87.
40. Liao Y, Takashima S, Asano Y, et al.: Activation of adenosine A1 receptor attenuatescardiac hypertrophy and prevents heart failure in murine left ventricular pressure-overload model. Circ Res 2003, 93:750-766.
41. Kennedy RH, Owings R, Joseph J, et al.: Acute dilatory and negative inotropic effects of homocysteine are inhibited by an adenosine blocker. Clin Exp Pharmacol Physiol 2006, 33:340-344.
42. Fabritz L, Kirchhof P, Fortmuller L, et al.: Gene dose-dependent atrial arrhythmias, heart block, and brady-cardiomyopathy in mice overexpressing A(3) adenosine receptors. Cardiovasc Res 2004, 62:500-508.